Kidney Disease
Constipation drug lubiprostone linked to kidney protection in CKD trial
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
Researchers at Tohoku University report that lubiprostone, a medication commonly used to treat chronic constipation, helped slow the decline of kidney function in patients with chronic kidney disease in a Phase II trial. The findings emerged from work exploring how gut health and constipation influence kidney outcomes.
UC Santa Barbara researchers report a dimeric IgA monoclonal antibody that can cross cyst-lining epithelia and dampen cMET signaling in polycystic kidney disease. In rodent models, it accumulated inside cysts, reduced pathway activity and slowed disease without apparent harm to healthy tissue, according to the study and the university’s release.
An Ruwaito ta hanyar AI An Binciki Gaskiya
A Lancet analysis estimates that nearly 800 million adults were living with chronic kidney disease in 2023—up from 378 million in 1990—with the illness now ranking ninth among global causes of death. Researchers urge earlier detection and wider access to proven treatments.